Related Experiment Video

Updated: Jan 21, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

[Research progress of hepatitis B and C virus co-infection]

L L Yan1, H Tang

  • 1Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China;Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610041 , China.

Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|July 31, 2019
PubMed

Insights

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-infection is common in high-prevalence areas. Co-infection can worsen liver disease and increase cancer risk, with potential for HBV reactivation during treatment.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis B virus (HBV) and Hepatitis C virus (HCV) share transmission routes, leading to frequent co-infection in endemic regions.
  • Reported co-infection rates vary globally, and silent HBV infections contribute to underestimation of true prevalence.
  • HCV may inhibit HBV replication, while HBV's effect on HCV requires further investigation.

Purpose of the Study:

  • To review the epidemiology, clinical implications, and treatment considerations of HBV/HCV co-infection.
  • To highlight the complexities of viral interactions and immune responses in co-infected individuals.
  • To assess treatment outcomes and the risk of HBV reactivation.

Main Methods:

  • Literature review of studies on HBV/HCV co-infection.
  • Analysis of epidemiological data and clinical outcomes.
  • Evaluation of treatment efficacy and safety profiles.

Main Results:

  • HBV/HCV co-infection is associated with more severe liver disease, including cirrhosis and increased liver cancer risk.
  • Peginterferon plus ribavirin shows similar efficacy to HCV monotherapy.
  • HBV reactivation is a risk during anti-HCV treatment, necessitating further research on prevention and management.

Conclusions:

  • HBV/HCV co-infection poses significant health risks, including accelerated liver disease progression.
  • Current treatment paradigms require careful consideration of HBV reactivation potential.
  • Further research is crucial to understand viral interactions and optimize management strategies for co-infected patients.

Keywords:
Hepatitis B virusInfectionReactivation

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K

Related Concept Videos

What are Viruses?00:50

What are Viruses?

Overview
127.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
260
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.5K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K